JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
143.93
-0.75 (-0.52%)
As of 11:33AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close144.68
Open145.02
Bid144.12 x 1000
Ask144.16 x 400
Day's Range143.82 - 145.21
52 Week Range118.62 - 148.32
Volume1,902,844
Avg. Volume6,574,747
Market Cap386.017B
Beta (3Y Monthly)0.31
PE Ratio (TTM)252.95
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.60 (2.47%)
Ex-Dividend Date2018-11-26
1y Target EstN/A
Trade prices are not sourced from all markets
  • Here’s how to easily reduce your investment risk just at the right time
    MarketWatch41 minutes ago

    Here’s how to easily reduce your investment risk just at the right time

    Mike Loewengart of E-Trade discusses equal-weighted and bond ETFs, and actively managed funds for diversification.

  • Gauging Analysts’ Views on TransEnterix Stock
    Market Realist4 hours ago

    Gauging Analysts’ Views on TransEnterix Stock

    In November, of the five analysts covering TransEnterix (TRXC), three have given it “buy” or higher ratings, and two have given it “hold” ratings. 

  • Financial Times14 hours ago

    [$$] The Theranos tale exposes the dangers lurking in Silicon Valley

    At some point, probably next year, Elizabeth Holmes, the charismatic founder of Theranos, and her ex-boyfriend Ramesh “Sunny” Balwani, the group’s former chief operating officer, will stand trial, charged with defrauding investors, doctors and patients. Somewhere among the court reporters will be investigative journalist John Carreyrou, completing an assignment that started in February 2015 when he received a tip about Ms Holmes, a Silicon Valley prodigy promising to shake up healthcare with a revolutionary blood-testing system. , his first book, which chronicles the rise and fall of Theranos.

  • 3 Top Healthcare Stocks to Buy in November
    Motley Fool16 hours ago

    3 Top Healthcare Stocks to Buy in November

    An insurer, a medical device company, and a healthcare Goliath could all be smart additions to portfolios this month.

  • Understanding TransEnterix’s Operational Performance
    Market Realist23 hours ago

    Understanding TransEnterix’s Operational Performance

    For 2018 and 2019, TransEnterix’s gross margins are expected to be 41.40% and 48.76%, respectively, compared to its gross margin of 5.4% in 2017. In comparison, the 2018 gross margins of its peers Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), and Stryker (SYK) are expected to be 71.01%, 70.43%, and 66.29%, respectively. TransEnterix incurred general and administrative expenses of $3.69 million in the third quarter compared to $2.92 million in the third quarter of 2017 primarily due to higher personnel costs and outsourced services expenses.

  • How TransEnterix Has Been Performing in November
    Market Realist23 hours ago

    How TransEnterix Has Been Performing in November

    TransEnterix (TRXC) is a medical device company focused on digitizing the interface between surgeons and patients for the improvement of minimally invasive surgery. TransEnterix’s Senhance surgical system digitizes laparoscopic minimally invasive surgery and allows for robotic precision, haptic feedback, surgeon camera control, and improved ergonomics. TransEnterix generated total revenue of $5.42 million in the third quarter compared to $183,000 in the comparable period of 2017.

  • Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
    Zacks2 days ago

    Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

    Johnson & Johnson (JNJ) closed at $145.62 in the latest trading session, marking a +0.19% move from the prior day.

  • Stock Market Power Rankings: Last Call for Facebook
    Motley Fool2 days ago

    Stock Market Power Rankings: Last Call for Facebook

    They're big, beautiful, and ranked from 1 to 50.

  • Hedge Fund Sentiment is Turning Against Johnson & Johnson (JNJ)
    Insider Monkey3 days ago

    Hedge Fund Sentiment is Turning Against Johnson & Johnson (JNJ)

    Insider Monkey finished processing more than 700 13F filings made by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of June 30. What do these smart investors think about Johnson & Johnson (NYSE:JNJ)? Overall, they’re fairly bullish on the stock, as 10.2% of the hedge funds tracked by Insider Monkey’s […]

  • 7 Dividend Stocks With Rising Payouts
    InvestorPlace5 days ago

    7 Dividend Stocks With Rising Payouts

    Investing in dividend stocks does seem like a relatively safe approach. This is especially the case when targeting large, stable companies.

  • 5 Dow Stocks to Sell (And 2 to Buy)
    Kiplinger5 days ago

    5 Dow Stocks to Sell (And 2 to Buy)

    Most stocks have been thoroughly shaken and stirred since early October, and a long-overdue corrective move finally took shape. Not even the bluest of the blue chips have been immune. The Dow Jones Industrial Average still is off its record high from a couple months ago, and several Dow stocks still are vulnerable to more selling. The initial shellshock has started to fade, however, the smoke is clearing and some stocks are recovering. Smart investors are now weighing the impact and searching for opportunities. Some Dow Jones stocks may have more downside to dish out, but a handful of these iconic names are looking oversold, undervalued and ripe for a rebound sooner than later. Remember: Corporate earnings have never been better, and consumer confidence is as high as it's been in years. Clearly something is going right. Here's a look at five Dow stocks that may have more ground to give up before they hit bottom, and two industrial-average components that may already be buys at current prices. But a note: Most of these "stocks to sell" are merely in short-term trouble. A sizable pullback from any of them could ultimately turn into a buying opportunity. SEE ALSO: 12 Vulnerable Stocks to Watch on Market-Wide Weakness

  • How Analysts View Alexion Stock
    Market Realist5 days ago

    How Analysts View Alexion Stock

    In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Alexion Pharmaceuticals stock is 1.83 with a target price of $163.29, implying an upside potential of 28.4% over Alexion Pharmaceuticals’ closing price of $127.18 on November 10, 2018.

  • Analyzing Alexion Pharmaceuticals’ Dicerna Collaboration
    Market Realist5 days ago

    Analyzing Alexion Pharmaceuticals’ Dicerna Collaboration

    In October 2018, Alexion Pharmaceuticals (ALXN) entered a collaboration with Dicerna Pharmaceuticals that provides Alexion exclusive worldwide licenses and development and commercial rights to two molecules for complement-mediated diseases along with an exclusive option for other molecules for two additional targets within the complement pathway. Under the collaboration, Alexion will make an upfront payment of $37.0 million and could be required to pay up to ~$625.0 million in milestone payments and royalties on product sales.

  • Healthcare ETF (JHMH) Hits New 52-Week High
    Zacks6 days ago

    Healthcare ETF (JHMH) Hits New 52-Week High

    This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?

  • A Look at Alexion Pharmaceuticals’ Operational Performance
    Market Realist6 days ago

    A Look at Alexion Pharmaceuticals’ Operational Performance

    For fiscal 2018 and 2019, Alexion Pharmaceuticals’ gross margins are expected at 91.08% and 91.22%, respectively, as compared with gross margins of 91.95% for fiscal 2017. In comparison, fiscal 2018 gross margins for peers Abbott Laboratories (ABT), Amgen (AMGN), and Johnson & Johnson (JNJ) are expected at 59.29%, 85.73%, and 70.43%, respectively. Alexion Pharmaceuticals incurred selling, general, and administrative expenses of $258.7 million in the third quarter of 2018 as compared with $270.6 million in the third quarter of 2017.

  • Analyzing Alexion Pharmaceuticals’ Product Performance
    Market Realist6 days ago

    Analyzing Alexion Pharmaceuticals’ Product Performance

    Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma. Total Soliris sales increased from $755.4 million in the third quarter of 2017 to $888.0 million in the latest quarter. Its US sales increased from $307.6 million in the third quarter of 2017 to $404.5 million in the latest quarter. Its Europe sales increased from $248.4 million in the third quarter of 2017 to $262.1 million in the latest quarter.

  • How Alexion Is Positioned in November
    Market Realist6 days ago

    How Alexion Is Positioned in November

    Alexion Pharmaceuticals (ALXN), a global biopharmaceutical company, is a leader in complement inhibition and is focused on the therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has brought to market the only approved complement inhibitor for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Further, the company has two enzyme replacement therapies for hypophosphatasia and lysosomal acid lipase deficiency.

  • Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ
    Zacks6 days ago

    Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ

    Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q3. The top line betters estimates.

  • The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Lockheed Martin and Boeing
    Zacks6 days ago

    The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Lockheed Martin and Boeing

    The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Lockheed Martin and Boeing

  • Investopedia6 days ago

    Merck and Johnson & Johnson Shares Show Big Buying

    Gains of 13.35% and 11.09% the past three months for shares of Merck & Co., Inc. ( MRK) and Johnson & Johnson ( JNJ) tell a story of unusual bullish trading activity accompanying the moves. The main criteria we look for when betting on upside in a stock are improving fundamentals, leading technicals and bullish trading activity in the shares. Beginning in August, shares of Merck and Johnson & Johnson have increased in price alongside large increases in volume.

  • Democrats Hold Edge in House Battle: 5 Great Picks (Revised)
    Zacks6 days ago

    Democrats Hold Edge in House Battle: 5 Great Picks (Revised)

    Drug and defense stocks would hugely benefit from a divided Congress.

  • Cramer on Washington gridlock: Buy fast growers
    CNBC Videos7 days ago

    Cramer on Washington gridlock: Buy fast growers

    Jim Cramer recommends stocks like Amazon and Apple in the wake of the 2018 midterm elections, in which Democrats regained control of the House of Representatives.

  • Cramer's advice on investing during Washington gridlock: ...
    CNBC Videos7 days ago

    Cramer's advice on investing during Washington gridlock: ...

    Jim Cramer recommends stocks like Amazon and Apple in the wake of the 2018 midterm elections, in which Democrats regained control of the House of Representatives.